Human chorionic gonadotropin–positive seminoma patients: A registry compiled by the global germ cell tumor collaborative group (G3)

C Seidel; G Daugaard; T Nestler; A Tryakin; M Fedyanin; C Fankhauser; T Hermanns; J Aparicio; J Heinzelbecker; P Paffenholz; A Heidenreich; U De Giorgi; R Cathomas; A Lorch; A Fingerhut; F Gayer; F Bremmer; P Giannatempo; A Necchi; G Aurilio; C Casadei; B Tran; KP Dieckmann; M Brito; C Ruf; C Oing; C Bokemeyer

Journal article

Human chorionic gonadotropin–positive seminoma patients: A registry compiled by the global germ cell tumor collaborative group (G3)

C Seidel, G Daugaard, T Nestler, A Tryakin, M Fedyanin, C Fankhauser, T Hermanns, J Aparicio, J Heinzelbecker, P Paffenholz, A Heidenreich, U De Giorgi, R Cathomas, A Lorch, A Fingerhut, F Gayer, F Bremmer, P Giannatempo, A Necchi, G Aurilio Show all

European Journal of Cancer | Published : 2020

DOI: 10.1016/j.ejca.2020.03.022

Abstract

Background: The prognostic role of human chorionic gonadotropin (hCG) and lactate dehydrogenase (LDH) serum levels in seminoma patients remains uncertain. This observational study evaluates the prognostic impact of tumour marker levels, and other clinicopathological findings, in hCG-positive seminoma patients. Methods: Seminoma patients with serum hCG levels above normal at first diagnosis were eligible for recruitment. Statistical analysis, including multivariate regression, was performed to identify risk factors. Primary end-points were overall survival (OS) and recurrence-free survival (RFS). Results: We recruited 1031 hCG-positive patients (stage I: n = 586; stage II + III: n = 427) diag..

View full abstract